SAN DIEGO, Aug. 10, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), disclosed a clinical trial collaboration with Paul Rolan, M.D., FRACP. Professor Rolan is a headache and pain specialist in the Clinical Pharmacology department at the University of Adelaide, Australia, and is initiating a Phase 2 trial of ibudilast (MN-166/AV411) as a potential new pharmacotherapy for medication overuse headache (MOH). He previously collaborated with MediciNova’s subsidiary, Avigen, in a Phase 1b/2a trial of ibudilast in chronic neuropathic pain. The Investigator-initiated (and Investigator-funded) MOH trial has cleared necessary reviews and MediciNova will provide regulatory support and active drug and placebo product for the trial.
